Developer docs
API playgroundTry for free, no card

Search company profiles

Edison Scientific

Full company profile

uuid009aec8

Namestring
Edison Scientific
Legal namestring
Edison Scientific, Inc.
Company typeenum
Private
Founded yearint
2025
Descriptiontext

Edison Scientific, Inc. is a Delaware-incorporated, privately held AI company headquartered in San Francisco that builds Kosmos, an "AI Scientist" platform designed to execute end-to-end biopharma R&D workflows — from target identification through clinical development and regulatory filing — autonomously. Kosmos is built on structured scientific "world models" that maintain coherence across tens of millions of tokens and is composed of specialized sub-agents: Edison Literature (a PaperQA3-based deep research agent reading figures, tables, and formulas across 150M+ papers, patents, and clinical trials), Edison Analysis (a Jupyter-native scientific coding agent executing Python/R/Bash), Edison Molecules (a chemistry agent with 30+ tools for retrosynthesis, ADMET, and toxicity), and Edison Precedent. Training and fine-tuning use the open-source Aviary framework integrated with NVIDIA NeMo Gym and NeMo RL, and the platform is model-agnostic. The company is the 2025 commercial spinout of the FutureHouse non-profit, co-founded by CEO Sam Rodriques and CTO Andrew White, who originated ChemCrow, PaperQA, Aviary, and ether0.

Edison monetizes through a mix of usage-based pay-as-you-go credits (Kosmos launched at $200 per run, 200 credits at $1/credit), subscription plans with monthly credit allocations plus non-expiring add-on credits, a freemium academic tier via the Edison Playground (10 free credits/month plus a one-time 2,000-credit block for existing academics), and quote-based Master Services Agreements for enterprise biopharma deployments. Enterprise contracts bundle SOC 2 Type II-compliant on-prem deployment, forward-deployed scientists, and custom world models fine-tuned via RL and supervised fine-tuning on partner data; the flagship example is the strategic collaboration with Incyte Corporation covering target discovery, target validation, and translational biology. Distribution is hybrid: enterprise field sales to biopharma R&D teams, a self-serve platform at platform.edisonscientific.com, a public Python API/SDK, and embedded workflow integrations (Slack, Teams, email, ELNs).

The company closed a $70 million seed round in December 2025 co-led by Spark Capital and Triatomic Capital (with a related SEC Form D filing for ~$68.89M), holds SOC 2 Type II certification, and operates with a small founding leadership team of ~8-9 named executives and members of technical staff. Edison also authors and maintains the scientific AI community's de facto evaluation benchmarks (LABBench2, BixBench, BixBench-Hypothesis, ether0), publishes open-source frameworks (PaperQA, Aviary, hypotest), and has been featured at NVIDIA GTC 2026, in CB Insights' Early-Stage AI Trends Report, and in tier-one press including Bloomberg and Forbes.

Short descriptiontext

Edison Scientific is an AI company building Kosmos, an autonomous AI Scientist platform that executes end-to-end biopharma R&D workflows from target discovery through clinical development, serving biopharma enterprise customers, academic researchers, and institutions via subscriptions, usage-based credits, and enterprise MSAs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, autonomous scientific research, biopharma R&D platform, AI scientist agents, computational biology tools
Industry2 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAN
Knowledge Management & Scientific Collaboration / Literature Intelligence
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Prepackaged Software7372
Product category
AI Drug Discovery Platform
Social media profiles1 record
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model4 records
1Subscription plans (Monthly Plan Credits)
TypeSubscription Recurring
Description

Recurring subscription Plans with a defined Initial Term and automatic Renewal Terms. Plans come with a base level of Monthly Plan Credits that reset at the start of every Renewal Term; unused credits expire. Plans are specified on the public pricing page.

edisonscientific.com
2Usage-based pay-as-you-go credits (per-run)
TypeUsage Based
Description

Kosmos launched at $200 per run (200 credits at $1/credit), with Founding Subscriptions locking in the $1/credit price. Add-On Credits can be purchased separately, do not reset or expire, and are used after Monthly Plan Credits are exhausted.

edisonscientific.com
3Enterprise Master Services Agreements (MSA)
TypeManaged Services
Description

Enterprise contracts governed by MSAs and Data Processing Agreements (DPAs) for biopharma R&D deployments; example includes the Incyte strategic collaboration embedding Kosmos into discovery and development. Forward-deployed scientists and custom world models are part of the enterprise offering.

edisonscientific.com
4Freemium / academic tier
TypeFreemium
Description

Edison Playground provides Literature, Analysis, and Precedent agents with 10 free credits per month; existing academic subscribers receive a one-time 2,000-credit block grant (in lieu of the prior 650/month), supporting a long-term freemium funnel for the academic community.

edisonscientific.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details5 tiers
1Kosmos usage — $200 per run (200 credits × $1/credit)
ModelUsage-basedBilling cadencePay-as-you-go
Notes

$1 per credit; 200 credits per Kosmos run; Founding Subscriptions lock in the $1/credit price. Heavily discounted at launch.

edisonscientific.com
2Subscription Plans with Monthly Plan Credits
ModelSubscriptionBilling cadenceMonthly
Notes

Initial Term + automatic Renewal Terms; Monthly Plan Credits reset each Renewal Term; unused credits expire; tier-specific credit amounts listed on pricing page.

edisonscientific.com
3Add-On Credits (non-expiring)
ModelUsage-basedBilling cadencePay-as-you-go
Notes

Purchased on top of subscription; do not reset or expire; consumed after Monthly Plan Credits are exhausted.

edisonscientific.com
4Edison Playground (free tier for academics)
ModelFreemiumBilling cadenceMonthly
Notes

10 free credits/month for Literature, Analysis, and Precedent agents; existing academics receive a one-time 2,000-credit block grant instead of the prior 650/month; updated free tier launching in a few months.

edisonscientific.com
5Enterprise MSA pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based; not publicly disclosed; governed by Master Services Agreement and Data Processing Agreement. Includes forward-deployed scientists, custom world models, and SOC 2 Type II on-prem deployment.

edisonscientific.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1Kosmos
Description

Edison's flagship AI Scientist platform for R&D teams; performs autonomous scientific investigations across the full biopharma R&D lifecycle, from hypothesis generation to clinical development.

edisonscientific.com
+4 more records
Core offering1 text field

Edison Scientific offers an AI Scientist platform called Kosmos that autonomously executes end-to-end biopharma R&D workflows from target identification through clinical development and filing, by orchestrating specialized agents for literature research (Edison Literature on PaperQA3), scientific data analysis (Edison Analysis in Jupyter notebooks), and chemistry reasoning (Edison Molecules with 30+ tools). The platform is delivered through enterprise Master Services Agreements with on-prem SOC 2 Type II deployment and forward-deployed scientists, alongside a self-serve web platform with monthly subscription credits, pay-as-you-go usage ($200/run, $1/credit), a Python API, and a freemium Edison Playground tier for academic researchers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 9 values shown
  • Kosmos run = ~6 months of human scientist work (beta user estimate, 6.14-month average across 7 scientists for 20-step runs)
+8 more records
Product overview1 text field

Edison Scientific offers a platform-plus-modules AI architecture for scientific R&D, built around Kosmos — its flagship AI Scientist for biopharma R&D that orchestrates end-to-end workflows from hypothesis generation to clinical development. The platform exposes three specialized agents that can be used individually or composed by Kosmos: Edison Literature (a deep research agent built on PaperQA3 that searches over 150M+ papers, patents, and clinical trials), Edison Analysis (a Jupyter-native data analysis agent that executes Python/R/Bash and integrates with the top 20 biomedical databases via its search_and_retrieve tool), and Edison Molecules (a chemistry agent with 30+ specialized tools covering retrosynthesis, ADMET, and toxicity). The commercial platform is complemented by the Edison Playground, a free-tier research environment that hosts Literature, Analysis, and Precedent agents. Underpinning the platform are Edison's open-source research artifacts — the PaperQA3 framework, the Aviary RL training framework, the ether0 chemical reasoning model, and the LABBench2, BixBench, and BixBench-Hypothesis benchmarks.

Product and service8 records
1Kosmos AI Scientist
CategoryAI Scientist Platform
Description

Edison's flagship AI Scientist agent that autonomously executes end-to-end biopharma R&D workflows from hypothesis to registration for biopharma R&D teams. Reads literature, analyzes data, generates hypotheses, steers investigations mid-run, branches hypotheses, and integrates with Slack, Teams, and email for synchronous collaboration.

2New Kosmos (Biopharma R&D Edition)
CategoryAI Scientist Platform
Description

Rebuilt Kosmos platform covering the full biopharma R&D lifecycle from target identification through clinical development and filing, for biopharma R&D teams and forward-deployed enterprise deployments.

3Edison Literature
CategorySpecialized AI Agent
Description

Deep research and information retrieval agent that searches and synthesizes over 175M+ scientific articles, patents, and clinical trials with multimodal figure and table understanding. Powers the literature search component of Kosmos and is available individually via the platform and API.

4Edison Analysis
CategorySpecialized AI Agent
Description

Science-native data analysis agent that iteratively updates Jupyter notebooks with Python, R, and Bash in a Docker environment; integrates search_and_retrieve specialist connectors to ~20 priority scientific data sources including Zenodo, PDB, ClinicalTrials.gov, GEO, CCLE, and GDSC. Reaches 46% on BixBench and 70% on Biomni Eval1.

5Edison Molecules
CategorySpecialized AI Agent
Description

Chemistry-specialized agent that unifies synthesis planning, molecular property prediction, safety assessment, and chemical data retrieval via 30+ specialized chemistry tools including retrosynthesis planners, ADMET predictors, toxicity models, and interfaces to ChEMBL, PubChem, and Chem-space.

6Edison Playground
CategoryFree-Tier Platform
Description

Public free-tier access to Edison's core research agents—Literature, Analysis, and Precedent—with 10 free credits per month for all users. Provides an entry point for academics and individual researchers to use Edison's agents.

7Enterprise Kosmos Deployment (MSA)
CategoryEnterprise Service
Description

Enterprise deployment of Kosmos under a Master Services Agreement and Data Processing Agreement, including forward-deployed scientists, custom world models built on partner data, on-prem SOC 2 Type II deployment, full governance and auditability, and trainable architecture supporting RL and supervised fine-tuning on partner data.

8Edison Client API & SDK
CategoryDeveloper API
Description

Python Edison Client SDK and API providing programmatic access to Edison's agents (literature-20260216, literature-20260216-high, Edison Analysis, Edison Molecules, and Kosmos) for enterprise and academic integration, documented in the Edison Cookbook.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierIndustry Ecosystem / Co-Adoption By IncyteTypeOthersAnnounced on2026-05-24
Description

Incyte expanded its AI drug discovery capabilities through parallel partnerships with Genesis Molecular AI and Edison Scientific, integrating both platforms into its R&D workflows. Edison is co-listed with Genesis as a partner of Incyte (not a direct Edison partner).

Strategic tierFlagship Enterprise PartnerTypeStrategic or Co-development PartnerAnnounced on2026-05-19
Description

Strategic collaboration to deploy the Kosmos AI platform across Incyte's drug discovery and development lifecycle, initially focused on target discovery, target validation, and translational biology. Both teams will measure impact on decision quality and pipeline productivity as the deployment expands across Incyte's broader R&D organization. Patrick Mayes, EVP & CSO of Incyte, provided a quote.

Strategic tierCore Infrastructure PartnerTypeTechnology or IntegrationAnnounced on2026-03-16
Description

Deep technology partnership across NVIDIA NeMo (Gym, RL), Nemotron 3, and Nemotron Parse. Edison trains Kosmos agents using Aviary + NeMo Gym/RL with GRPO and FP8 RL on Nemotron models; Nemotron Parse powers Edison Literature's figure/table extraction. NVIDIA published a case study and tech blog on the integration. BixBench-Hypothesis and BBH-Train were co-developed with NVIDIA.

Strategic tierResearch CollaborationTypeStrategic or Co-development PartnerAnnounced on2026-02-17
Description

Co-developed LABBench2 (1,900-task benchmark for AI in scientific work) alongside FutureHouse and the Broad Institute. LABBench2 is published on Hugging Face (futurehouse/labbench2) with the harness on GitHub.

Strategic tierResearch CollaborationTypeStrategic or Co-development PartnerAnnounced on2026-02-17
Description

Co-developed LABBench2 with Edison Scientific, UC Berkeley, and FutureHouse. The benchmark covers 1,892 tasks across 11 categories for evaluating AI systems in scientific work.

Strategic tierFoundational Origin / Continuing CollaborationTypeStrategic or Co-development PartnerAnnounced on2025-11-05
Description

Edison Scientific is the commercial spinout of the FutureHouse non-profit. Founders Sam Rodriques and Andrew White co-run both organizations with conflict-of-interest controls. FutureHouse continues to focus on basic research and educational access, while Edison scales the AI Scientist commercially. Edison inherited the Robin, PaperQA, ChemCrow, ether0, and Aviary projects from FutureHouse.

Strategic tierOperational VendorTypeOthers
Description

Processes all Edison subscription and credit payments through a PCI-DSS-compliant flow. Edison Scientific does not store full payment card information; Stripe shares limited transactional data (payment status, billing country) with Edison.

8Tony Kulesa / Pillar VC
Strategic tierBoard / Governance ConnectionTypeStrategic or Co-development Partner
Description

Tony Kulesa, Partner at Pillar VC and a founding board member of FutureHouse, is listed as Executive Director on Edison's team page, maintaining the link between Edison and Pillar VC's biotech/deep tech portfolio (Latent Labs, Nabla Bio, Portal Biotech, Amber Bio, Rowan Science).

edisonscientific.com
Strategic tierAcademic Research CollaborationTypeStrategic or Co-development Partner
Description

Tonio Buonassisi, Professor of Mechanical Engineering at MIT (MIT logo shown on Edison's homepage as a trusted partner), provided a public testimonial about Kosmos executing ~292 independent analysis trajectories in 24 hours. The article also references University of Rochester-led LLM-driven materials discovery work as part of the broader research ecosystem Edison operates in.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Generative AI drug creation company combining AI denovo design with a proprietary wet-lab platform to deliver novel antibody therapeutics. Comparable to Edison in merging AI-driven design with end-to-end biopharma execution.

TypeDirect peer
Description

AI-biotech applying ML to patient-derived data for drug discovery, translational research, and clinical development. Comparable to Edison as an AI platform targeting the biopharma R&D-to-clinical lifecycle with research-grade infrastructure.

3Isomorphic Labs
TypeBroad incumbent
Description

Alphabet-backed commercial drug discovery spinout from DeepMind building an AI-first drug design engine. Comparable to Edison as a well-capitalized, full-lifecycle AI drug discovery effort, though with broader financial and compute resources.

TypeDirect peer
Description

AI-driven precision medicine company using AI to design and develop novel therapeutics, with end-to-end discovery-to-clinical capabilities. Comparable to Edison's Kosmos as a full-lifecycle AI drug discovery platform.

TypeDirect peer
Description

ML-driven drug discovery company combining generative biology, data generation, and ML models to accelerate therapeutic discovery. Compares to Edison in its ambition to bring AI into the biopharma R&D loop end-to-end.

TypeDirect peer
Description

AI-native biopharma combining high-throughput wet-lab experimentation with ML models to discover and develop new therapeutics. Directly comparable to Edison as a vertically integrated AI-for-drug-discovery platform targeting the full R&D lifecycle.

TypeDirect peer
Description

Generative and predictive AI platform for small-molecule drug discovery; co-listed as an Incyte partner alongside Edison. Compares to Edison's Molecules agent and Kosmos's chemistry reasoning capabilities.

TypeOthers
Description

Cloud platform for scientific R&D data management (ELNs, sample tracking, molecular biology). Adjacent rather than directly competitive: Benchling manages the laboratory data that Edison's Kosmos agents analyze and integrate via its search_and_retrieve tool.

TypeEmerging player
Description

AI-first drug design company focused on programmable biology, backed by Pillar VC (the same VC whose partner sits on Edison's board). Comparable as a frontier AI-for-biology emerging player targeting biopharma R&D acceleration.

TypeEmerging player
Description

AI platform focused on molecular structure prediction and protein design for drug discovery; featured alongside Edison on NVIDIA's Bio International Convention agentic-AI panel. Closely comparable in scope and emerging-player profile.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration14 records

Each record includes

Title, Type, Description, Source

AI capability13 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Edison Scientific

AI Drug Discovery Platformedisonscientific.com

Edison Scientific is an AI company building Kosmos, an autonomous AI Scientist platform that executes end-to-end biopharma R&D workflows from target discovery through clinical development, serving biopharma enterprise customers, academic researchers, and institutions via subscriptions, usage-based credits, and enterprise MSAs.

What Edison Scientific does

Edison Scientific, Inc. is a Delaware-incorporated, privately held AI company headquartered in San Francisco that builds Kosmos, an "AI Scientist" platform designed to execute end-to-end biopharma R&D workflows — from target identification through clinical development and regulatory filing — autonomously. Kosmos is built on structured scientific "world models" that maintain coherence across tens of millions of tokens and is composed of specialized sub-agents: Edison Literature (a PaperQA3-based deep research agent reading figures, tables, and formulas across 150M+ papers, patents, and clinical trials), Edison Analysis (a Jupyter-native scientific coding agent executing Python/R/Bash), Edison Molecules (a chemistry agent with 30+ tools for retrosynthesis, ADMET, and toxicity), and Edison Precedent. Training and fine-tuning use the open-source Aviary framework integrated with NVIDIA NeMo Gym and NeMo RL, and the platform is model-agnostic. The company is the 2025 commercial spinout of the FutureHouse non-profit, co-founded by CEO Sam Rodriques and CTO Andrew White, who originated ChemCrow, PaperQA, Aviary, and ether0.

Edison monetizes through a mix of usage-based pay-as-you-go credits (Kosmos launched at $200 per run, 200 credits at $1/credit), subscription plans with monthly credit allocations plus non-expiring add-on credits, a freemium academic tier via the Edison Playground (10 free credits/month plus a one-time 2,000-credit block for existing academics), and quote-based Master Services Agreements for enterprise biopharma deployments. Enterprise contracts bundle SOC 2 Type II-compliant on-prem deployment, forward-deployed scientists, and custom world models fine-tuned via RL and supervised fine-tuning on partner data; the flagship example is the strategic collaboration with Incyte Corporation covering target discovery, target validation, and translational biology. Distribution is hybrid: enterprise field sales to biopharma R&D teams, a self-serve platform at platform.edisonscientific.com, a public Python API/SDK, and embedded workflow integrations (Slack, Teams, email, ELNs).

The company closed a $70 million seed round in December 2025 co-led by Spark Capital and Triatomic Capital (with a related SEC Form D filing for ~$68.89M), holds SOC 2 Type II certification, and operates with a small founding leadership team of ~8-9 named executives and members of technical staff. Edison also authors and maintains the scientific AI community's de facto evaluation benchmarks (LABBench2, BixBench, BixBench-Hypothesis, ether0), publishes open-source frameworks (PaperQA, Aviary, hypotest), and has been featured at NVIDIA GTC 2026, in CB Insights' Early-Stage AI Trends Report, and in tier-one press including Bloomberg and Forbes.

Edison Scientific firmographics

Firmographics
Name
Edison Scientific
Legal name
Edison Scientific, Inc.
Website
https://edisonscientific.com
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
101–250 employees
Short description
Edison Scientific is an AI company building Kosmos, an autonomous AI Scientist platform that executes end-to-end biopharma R&D workflows from target discovery through clinical development, serving biopharma enterprise customers, academic researchers, and institutions via subscriptions, usage-based credits, and enterprise MSAs.
Ownership category
akta.pro rank

Edison Scientific industry classification

Industry
Product category
AI Drug Discovery Platform
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAN
Knowledge Management & Scientific Collaboration / Literature Intelligence
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • AI drug discovery
  • Autonomous scientific research
  • Biopharma R&D platform
  • AI scientist agents
  • Computational biology tools

Where Edison Scientific is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Edison Scientific business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Subscription plans (Monthly Plan Credits): Recurring subscription Plans with a defined Initial Term and automatic Renewal Terms. Plans come with a base level of Monthly Plan Credits that reset at the start of every Renewal Term; unused credits expire. Plans are specified on the public pricing page.
  2. Usage-based pay-as-you-go credits (per-run): Kosmos launched at $200 per run (200 credits at $1/credit), with Founding Subscriptions locking in the $1/credit price. Add-On Credits can be purchased separately, do not reset or expire, and are used after Monthly Plan Credits are exhausted.
  3. Enterprise Master Services Agreements (MSA): Enterprise contracts governed by MSAs and Data Processing Agreements (DPAs) for biopharma R&D deployments; example includes the Incyte strategic collaboration embedding Kosmos into discovery and development. Forward-deployed scientists and custom world models are part of the enterprise offering.
  4. Freemium / academic tier: Edison Playground provides Literature, Analysis, and Precedent agents with 10 free credits per month; existing academic subscribers receive a one-time 2,000-credit block grant (in lieu of the prior 650/month), supporting a long-term freemium funnel for the academic community.

Pricing tiers

ModelBillingPrice
Usage-basedPay-as-you-goKosmos usage — $200 per run (200 credits × $1/credit)
SubscriptionMonthlySubscription Plans with Monthly Plan Credits
Usage-basedPay-as-you-goAdd-On Credits (non-expiring)
FreemiumMonthlyEdison Playground (free tier for academics)
OtherMulti-year contractEnterprise MSA pricing

Go-to-market motion4 records

Distribution channels5 records

Marketing channels7 records

Edison Scientific product offering

Product offering

Core offering

Edison Scientific offers an AI Scientist platform called Kosmos that autonomously executes end-to-end biopharma R&D workflows from target identification through clinical development and filing, by orchestrating specialized agents for literature research (Edison Literature on PaperQA3), scientific data analysis (Edison Analysis in Jupyter notebooks), and chemistry reasoning (Edison Molecules with 30+ tools). The platform is delivered through enterprise Master Services Agreements with on-prem SOC 2 Type II deployment and forward-deployed scientists, alongside a self-serve web platform with monthly subscription credits, pay-as-you-go usage ($200/run, $1/credit), a Python API, and a freemium Edison Playground tier for academic researchers.

Product overview

Edison Scientific offers a platform-plus-modules AI architecture for scientific R&D, built around Kosmos — its flagship AI Scientist for biopharma R&D that orchestrates end-to-end workflows from hypothesis generation to clinical development. The platform exposes three specialized agents that can be used individually or composed by Kosmos: Edison Literature (a deep research agent built on PaperQA3 that searches over 150M+ papers, patents, and clinical trials), Edison Analysis (a Jupyter-native data analysis agent that executes Python/R/Bash and integrates with the top 20 biomedical databases via its search_and_retrieve tool), and Edison Molecules (a chemistry agent with 30+ specialized tools covering retrosynthesis, ADMET, and toxicity). The commercial platform is complemented by the Edison Playground, a free-tier research environment that hosts Literature, Analysis, and Precedent agents. Underpinning the platform are Edison's open-source research artifacts — the PaperQA3 framework, the Aviary RL training framework, the ether0 chemical reasoning model, and the LABBench2, BixBench, and BixBench-Hypothesis benchmarks.

Differentiator

Problem solved

Functional benefit

Brands

  • Kosmos: Edison's flagship AI Scientist platform for R&D teams; performs autonomous scientific investigations across the full biopharma R&D lifecycle, from hypothesis generation to clinical development.
  • Edison Analysis
  • Edison Literature
  • Edison Playground
  • Edison Labs

Products and services

  • Kosmos AI Scientist Edison's flagship AI Scientist agent that autonomously executes end-to-end biopharma R&D workflows from hypothesis to registration for biopharma R&D teams. Reads literature, analyzes data, generates hypotheses, steers investigations mid-run, branches hypotheses, and integrates with Slack, Teams, and email for synchronous collaboration.
  • New Kosmos (Biopharma R&D Edition) Rebuilt Kosmos platform covering the full biopharma R&D lifecycle from target identification through clinical development and filing, for biopharma R&D teams and forward-deployed enterprise deployments.
  • Edison Literature Deep research and information retrieval agent that searches and synthesizes over 175M+ scientific articles, patents, and clinical trials with multimodal figure and table understanding. Powers the literature search component of Kosmos and is available individually via the platform and API.
  • Edison Analysis Science-native data analysis agent that iteratively updates Jupyter notebooks with Python, R, and Bash in a Docker environment; integrates search_and_retrieve specialist connectors to ~20 priority scientific data sources including Zenodo, PDB, ClinicalTrials.gov, GEO, CCLE, and GDSC. Reaches 46% on BixBench and 70% on Biomni Eval1.
  • Edison Molecules Chemistry-specialized agent that unifies synthesis planning, molecular property prediction, safety assessment, and chemical data retrieval via 30+ specialized chemistry tools including retrosynthesis planners, ADMET predictors, toxicity models, and interfaces to ChEMBL, PubChem, and Chem-space.
  • Edison Playground Public free-tier access to Edison's core research agents—Literature, Analysis, and Precedent—with 10 free credits per month for all users. Provides an entry point for academics and individual researchers to use Edison's agents.
  • Enterprise Kosmos Deployment (MSA) Enterprise deployment of Kosmos under a Master Services Agreement and Data Processing Agreement, including forward-deployed scientists, custom world models built on partner data, on-prem SOC 2 Type II deployment, full governance and auditability, and trainable architecture supporting RL and supervised fine-tuning on partner data.
  • Edison Client API & SDK Python Edison Client SDK and API providing programmatic access to Edison's agents (literature-20260216, literature-20260216-high, Edison Analysis, Edison Molecules, and Kosmos) for enterprise and academic integration, documented in the Edison Cookbook.

Quantifiable outcome

  • Kosmos run = ~6 months of human scientist work (beta user estimate, 6.14-month average across 7 scientists for 20-step runs)
  • +8 more outcomes

Companies that use Edison Scientific

Customer profile

Named customers4 records

Ideal customer profiles3 records

Edison Scientific technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration14 records

AI capability13 records

Feature10 records

Edison Scientific partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered industry ecosystem / co-adoption by incyte, flagship enterprise partner, core infrastructure partner, research collaboration, foundational origin / continuing collaboration, operational vendor, board / governance connection and academic research collaboration.

  • Genesis Molecular AIindustry ecosystem / co-adoption by incyteOthers · 24 May 2026Incyte expanded its AI drug discovery capabilities through parallel partnerships with Genesis Molecular AI and Edison Scientific, integrating both platforms into its R&D workflows. Edison is co-listed with Genesis as a partner of Incyte (not a direct Edison partner).
  • Incyte Corporationflagship enterprise partnerStrategic or Co-development Partner · 19 May 2026Strategic collaboration to deploy the Kosmos AI platform across Incyte's drug discovery and development lifecycle, initially focused on target discovery, target validation, and translational biology. Both teams will measure impact on decision quality and pipeline productivity as the deployment expands across Incyte's broader R&D organization. Patrick Mayes, EVP & CSO of Incyte, provided a quote.
  • NVIDIAcore infrastructure partnerTechnology or Integration · 16 March 2026Deep technology partnership across NVIDIA NeMo (Gym, RL), Nemotron 3, and Nemotron Parse. Edison trains Kosmos agents using Aviary + NeMo Gym/RL with GRPO and FP8 RL on Nemotron models; Nemotron Parse powers Edison Literature's figure/table extraction. NVIDIA published a case study and tech blog on the integration. BixBench-Hypothesis and BBH-Train were co-developed with NVIDIA.
  • UC Berkeleyresearch collaborationStrategic or Co-development Partner · 17 February 2026Co-developed LABBench2 (1,900-task benchmark for AI in scientific work) alongside FutureHouse and the Broad Institute. LABBench2 is published on Hugging Face (futurehouse/labbench2) with the harness on GitHub.
  • Broad Instituteresearch collaborationStrategic or Co-development Partner · 17 February 2026Co-developed LABBench2 with Edison Scientific, UC Berkeley, and FutureHouse. The benchmark covers 1,892 tasks across 11 categories for evaluating AI systems in scientific work.
  • FutureHousefoundational origin / continuing collaborationStrategic or Co-development Partner · 5 November 2025Edison Scientific is the commercial spinout of the FutureHouse non-profit. Founders Sam Rodriques and Andrew White co-run both organizations with conflict-of-interest controls. FutureHouse continues to focus on basic research and educational access, while Edison scales the AI Scientist commercially. Edison inherited the Robin, PaperQA, ChemCrow, ether0, and Aviary projects from FutureHouse.
  • Stripe, Inc.operational vendorOthersProcesses all Edison subscription and credit payments through a PCI-DSS-compliant flow. Edison Scientific does not store full payment card information; Stripe shares limited transactional data (payment status, billing country) with Edison.
  • Tony Kulesa / Pillar VCboard / governance connectionStrategic or Co-development PartnerTony Kulesa, Partner at Pillar VC and a founding board member of FutureHouse, is listed as Executive Director on Edison's team page, maintaining the link between Edison and Pillar VC's biotech/deep tech portfolio (Latent Labs, Nabla Bio, Portal Biotech, Amber Bio, Rowan Science).
  • University of Rochesteracademic research collaborationStrategic or Co-development PartnerTonio Buonassisi, Professor of Mechanical Engineering at MIT (MIT logo shown on Edison's homepage as a trusted partner), provided a public testimonial about Kosmos executing ~292 independent analysis trajectories in 24 hours. The article also references University of Rochester-led LLM-driven materials discovery work as part of the broader research ecosystem Edison operates in.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Edison Scientific competitors and assessment

Company assessment

Direct peers

  • Absci: Generative AI drug creation company combining AI denovo design with a proprietary wet-lab platform to deliver novel antibody therapeutics. Comparable to Edison in merging AI-driven design with end-to-end biopharma execution.
  • Owkin: AI-biotech applying ML to patient-derived data for drug discovery, translational research, and clinical development. Comparable to Edison as an AI platform targeting the biopharma R&D-to-clinical lifecycle with research-grade infrastructure.
  • Exscientia: AI-driven precision medicine company using AI to design and develop novel therapeutics, with end-to-end discovery-to-clinical capabilities. Comparable to Edison's Kosmos as a full-lifecycle AI drug discovery platform.
  • Insitro: ML-driven drug discovery company combining generative biology, data generation, and ML models to accelerate therapeutic discovery. Compares to Edison in its ambition to bring AI into the biopharma R&D loop end-to-end.
  • Recursion Pharmaceuticals: AI-native biopharma combining high-throughput wet-lab experimentation with ML models to discover and develop new therapeutics. Directly comparable to Edison as a vertically integrated AI-for-drug-discovery platform targeting the full R&D lifecycle.
  • Genesis Molecular AI: Generative and predictive AI platform for small-molecule drug discovery; co-listed as an Incyte partner alongside Edison. Compares to Edison's Molecules agent and Kosmos's chemistry reasoning capabilities.

Broad incumbents

  • Isomorphic Labs: Alphabet-backed commercial drug discovery spinout from DeepMind building an AI-first drug design engine. Comparable to Edison as a well-capitalized, full-lifecycle AI drug discovery effort, though with broader financial and compute resources.

Others

  • Benchling: Cloud platform for scientific R&D data management (ELNs, sample tracking, molecular biology). Adjacent rather than directly competitive: Benchling manages the laboratory data that Edison's Kosmos agents analyze and integrate via its search_and_retrieve tool.

Emerging players

  • Latent Labs: AI-first drug design company focused on programmable biology, backed by Pillar VC (the same VC whose partner sits on Edison's board). Comparable as a frontier AI-for-biology emerging player targeting biopharma R&D acceleration.
  • Chai Discovery: AI platform focused on molecular structure prediction and protein design for drug discovery; featured alongside Edison on NVIDIA's Bio International Convention agentic-AI panel. Closely comparable in scope and emerging-player profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Edison Scientific social profiles

Digital presence

Edison Scientific compliance and trust

Trust signal

Compliance1 record

Edison Scientific financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Edison Scientific leadership team

Management profile

Number of profiles

Profiles9 records

Edison Scientific funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Edison Scientific M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Edison Scientific

What does Edison Scientific do?

Edison Scientific offers an AI Scientist platform called Kosmos that autonomously executes end-to-end biopharma R&D workflows from target identification through clinical development and filing, by orchestrating specialized agents for literature research (Edison Literature on PaperQA3), scientific data analysis (Edison Analysis in Jupyter notebooks), and chemistry reasoning (Edison Molecules with 30+ tools). The platform is delivered through enterprise Master Services Agreements with on-prem SOC 2 Type II deployment and forward-deployed scientists, alongside a self-serve web platform with monthly subscription credits, pay-as-you-go usage ($200/run, $1/credit), a Python API, and a freemium Edison Playground tier for academic researchers.

Is Edison Scientific a public or private company?

Edison Scientific is a private company. It is classified as venture growth investor backed and is currently operating.

When was Edison Scientific founded?

Edison Scientific was founded in 2025. It employs 101 to 250 people.

Where is Edison Scientific based?

Edison Scientific is headquartered in San Francisco, United States, in the North America region.

How does Edison Scientific make money?

Four revenue lines are on record. Subscription plans (Monthly Plan Credits) is the primary driver. The others are usage-based pay-as-you-go credits (per-run), enterprise Master Services Agreements (MSA) and freemium / academic tier.

Who are Edison Scientific's main competitors?

Direct peers on record are Absci, Owkin, Exscientia, Insitro, Recursion Pharmaceuticals and Genesis Molecular AI. Isomorphic Labs is listed as a broad incumbent. Benchling is listed as an others. Emerging players are Latent Labs and Chai Discovery.

Does Edison Scientific have an API?

Yes. Edison Scientific provides a public API for programmatic access to its agents (Edison Analysis, Literature, and Kosmos) via the Edison platform at platform.edisonscientific.com. The API is documented in the Edison Cookbook as an "edison-client" tutorial and is available alongside the web-based platform for enterprise and academic integration. Developer documentation is at edisonscientific.gitbook.io/edison-cookbook/edison-client/docs/edison_analysis_tutorial.

What industry is Edison Scientific in?

Edison Scientific's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAN, Knowledge Management & Scientific Collaboration / Literature Intelligence. Its NAICS code is 5417 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooEdison Scientific Hires Former Palantir Healthcare Leader Lewis Woolfson as Head of Forward Deployed EngineeringEdison Scientific appointed Lewis Woolfson, former Palantir Healthcare Lead, as Head of Forward Deployed Engineering. He will lead teams embedding Kosmos AI into drugmakers' R&D and serve as site lead for Edison's New York City office. The appointment follows recent collaborations with Pfizer and Incyte.Business Wire BlogEdison Scientific Announces Agreement with Pfizer to Accelerate Research and DevelopmentEdison Scientific announced an agreement to deploy its Edison AI Platform and Kosmos AI scientist across Pfizer's biopharmaceutical research and development pipeline. Kosmos will access Pfizer's data to support scientists and accelerate discovery of potential new medicines. The collaboration aims to build integrated world models from Pfizer's internal drug development data.Mirage NewsPNNL's Lab-Wide Drive for Trustworthy Auto SciencePNNL's Center for Robotics and Autonomy is working to integrate automation and assured AI into scientific experiments, with a goal of autonomy touching every experiment within five years. The laboratory has launched the ARCADIA platform, which integrates AI agents, robotics, and data systems into a unified discovery ecosystem, backed by over $5 million in annual investment. PNNL is collaborating with industry partners including Amazon Web Services, Microsoft, Edison Scientific, and Ginkgo Bioworks to strengthen its technical foundation in autonomous science.BioSpaceIncyte Reports Second Quarter 2026 Financial Results and Provides Business UpdatesIncyte reported Q2 2026 total revenue of $1.67 billion and total net sales of $1.49 billion, up 38% and 40% year-over-year. The company raised its full-year 2026 net sales guidance to $5.13–5.26 billion, citing the Opzelura CMS agreement and Vega acquisition.ACCESS NewswireEdison Scientific and Population Health Partners Partner to Build the Next Generation of Biotech CompaniesEdison Scientific and Population Health Partners announced a partnership to build new biotech companies using AI to accelerate drug development. The collaboration will embed Edison's AI scientist Kosmos throughout the drug development lifecycle, with the first effort targeting a clinical-stage asset that could impact 10% of the world's population.STATAI scientist company Edison Scientific tapped by team behind Metsera to create new biotechsFutureHouse, an AI scientist company, received $30 million offers from two top-10 drugmakers for its AI agents. It spun off Edison Scientific in late 2025 with $70 million in venture funding. The company aims to scale scientific discovery with AI agents.STATAI scientist company Edison Scientific tapped by team behind Metsera to create new biotechsThe AI scientist company FutureHouse, founded in 2023, spun off Edison Scientific in late 2025 to meet the demand for a commercial product after receiving significant interest from top pharmaceutical companies for its AI agents in drug discovery. Edison Scientific was launched with $70 million in venture funding, indicating a strong market interest in its innovative approach. The founding team, including CEO Sam Rodriques and co-founder Andrew White, aims to enhance scientific discovery using AI technology.Business Wire BlogIncyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and DevelopmentIncyte and Edison Scientific announced a strategic collaboration to use Edison’s AI platform, Kosmos, in Incyte’s research and development processes. The partnership aims to enhance decision quality and pipeline productivity by integrating AI into target discovery, validation, and translational biology.FierceBiotechIncyte inks deal with Edison Scientific to train AI through drug discoveryIncyte has partnered with Edison Scientific to deploy its AI scientist platform Kosmos across Incyte's drug discovery and development workflows, starting with research applications and with potential expansion to broader R&D operations. The collaboration aims to leverage Incyte's translational and clinical data to build predictive models of therapeutic performance, with Edison's CEO emphasizing a model that learns continuously from experiments and clinical readouts. This deal reflects a broader industry trend where biopharma companies are increasingly integrating AI to accelerate drug discovery, improve experimental design, and shorten development timelines.BioSpaceIncyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and DevelopmentIncyte and Edison Scientific announced a strategic collaboration to use Edison's AI scientist Kosmos for Incyte's discovery and development work. The initial deployment targets target discovery, validation, and translational biology, with the goal of embedding AI to improve decision quality and pipeline productivity. The companies will measure impact as the system evolves.